Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential ...

Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...

Oculis’ neuroprotective candidate privosegtor receives US FDA breakthrough therapy designation to treat optic neuritis: Zug, Switzerland Thursday, January 8, 2026, 17:00 Hrs [IS ...

The US Food and Drug Administration has granted breakthrough therapy designation to Oculis’ neuroprotective candidate ...

Oculis Holding (OCS) added ~11% on Tuesday after the Swiss drug developer announced the breakthrough therapy designation for ...

A 71-year-old man was referred by his usual ophthalmologist to the neuro-ophthalmology clinic at Tufts Medical Center for bilateral decreased vision associated with bilateral optic disc edema. His ...

Sungkyunkwan University researchers in Korea ran a nationwide cohort analysis linking allergic diseases to increased optic neuritis risk, with allergic rhinitis showing the strongest association. A ...

Holding announced that its neuroprotective candidate Privosegtor was granted breakthrough therapy designation by the U.S. Food and ...

Investing.com -- Oculis Holding AG (NASDAQ:OCS) stock surged 9% on Tuesday after the FDA granted breakthrough therapy designation to its neuroprotective candidate Privosegtor for the treatment of ...